Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.

Abstract: A novel monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH), its use and a hybridoma strain NCK-J24 which produces the antibody. Since the monoclonal antibody produced by the hybridoma of the present invention recognizes GAPDH selectively and strongly, it can be used in screening and diagnosis of an apoptosis-concerning protein and prevention and/or treatment of neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, Huntington's disease, Machado-Joseph's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jacob's disease and the like) and GAPDH-concerning diseases (motor dysfunction and the like caused by spinal cord injury, spinal cord compression, cerebral ischemia, peripheral nerve injury and the like).

Abstract: A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and/or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.

Abstract: The present invention pertains to a monoclonal antibody, or fragment thereof, having an antigen-binding specific region for NKX3.1 and to a hybridoma cell line for producing the monoclonal antibody. The present invention also pertains to a method for detecting the presence of NKX3.1 in a sample. The method comprises (a) contacting a biopsy tissue sample with a monoclonal antibody, or a fragment thereof, having an antigen-binding specific region for NKX3.1, under conditions permitting immunospecific binding between the monoclonal antibody, or a fragment thereof, and NKX3.1 in the sample; and (b) detecting whether immunospecific binding has occurred to detect the presence of NKX3.1 in the sample.

Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.

Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C 19 levels in individuals relative to P450 2C19 levels in a control population.

Abstract: A cytochrome p450 14&agr;-demethylase enzyme isolated from Mycobacterium tuberculosis designated as MT CYP51. A crystalline form of MT CYP51 is also disclosed. Nucleic acid molecules encoding MT CYP51 are also disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to MT CYP51, and methods of producing the same, are also disclosed. MT CYP51 is characterized as having 14&agr;-demethylase biological activity. Thus, therapeutic and drug screening methods pertaining to this activity are also disclosed.

Abstract: Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof are used in pharmaceutical preparations and in diagnosis. Cells which express these antibodies, antibody fragments, mixtures or derivatives thereof are also disclosed.

Abstract: Antibodies, as well as binding fragments and mimetics thereof, that specifically bind to polyglutamine expansion containing proteins, e.g. mutant huntingtin protein, are provided. The subject binding agents, e.g. antibodies, fragments and mimetics thereof, etc., are characterized in that they bind to the target polyglutamine expansion containing protein in a manner that differs from the 1C2 antibody, e.g. in terms of affinity, avidity, and the like. Also provided are methods of screening compounds for polyglutamine expansion protein binding modulation activity, as well as pharmaceutical compositions of such agents. In addition, methods and devices for screening samples for the presence of polyglutamine expansion containing proteins, e.g. mutant huntingtin protein, are provided. Finally, nucleic acids encoding the subject antibodies and methods for their expression, including in therapeutic treatment protocols, are provided.

Abstract: Isolated and purified lipoxygenase proteins and nucleic acids are described. Particularly, a novel human 15(S) lipoxygenase (15-Lox-2) protein and cDNA and a cDNA for mouse 8S-lipoxygenase are described. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also described, along with methods of producing each. Isolated and purified antibodies to 15-Lox-2 and 8-Lox, and methods of producing the same, are also described.

Abstract: The application relates to the purification and characterization of a family of A-type inositolphosphoglycans (IPGs) from human liver and placenta. These substances are shown to have the biological activity associated with A-type IPG fractions, namely regulating lipogenic activity and inhibiting cAMP dependent protein kinase. The characterization of the compounds demonstrates that they contain metal ions, in particular Zn2+, and optionally phosphate. The compounds and their antagonists have uses as pharmaceuticals, e.g. for the treatment of diabetes, and in screening for synthetic analogs.

Abstract: The present invention provides a unique src-family kinase (SFK) that plays a key role in the transformation of early-stage embryonic cells to mesodermal cells. Furthermore, this src-family kinase is likely to be a proto-oncogene. The nucleic acid and amino acid sequences are disclosed.

Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.

Abstract: Monoclonal antibodies against dihydropyrimidine dehydrogenase are disclosed. Immunologic assays using the monoclonal antibodies are also disclosed.

Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nuclei acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.

Abstract: The invention relates generally to the Jak family of kinases. This includes the DNA and amino acid sequences for Jak 3 kinases. Additionally, the invention concerns expression vectors comprising DNA sequences encoding a Jak 3 kinase and host cell containing such expression vectors.

Abstract: The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods. The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind native hpHAse (anti-native hpHAse antibodies), and anti-native hpHAse antibodies identified by this screening method. The invention also features an assay for sensitive detection of HAse activity using biotinylated hyaluronic acid (bHA). Purification and characterization of hpHAse lead to the inventors' additional discovery that hpHAse is encoded by the LuCa-1 gene, which gene is present in the human chromosome at 3p21.3, a region associated with tumor suppression.

Abstract: Novel polypeptides called signaling inositol polyphosphate 5-phosphatases are described called SIP-130, SIP-125, and SIP-N. SIP-130 is capable of binding to aPTB domain of SH2 and collagen containing protein (SHC). Also provided are polynucleotide sequences encoding the novel polypeptides, as well as vectors and host cells containing the polynucleotides. Further provided are modulators including agonists and antagonists of the novel polypeptides for use as therapeutics, including antibodies, polypeptides, small molecules, and polynucleotides and methods of using the therapeutics in treatment of diseases associated with abnormal cell growth. Methods of making the polypeptides, polynucleotides, vectors, host cells, antibodies, and small molecules are also provided. Gene delivery vehicles including SIP and SIP activity-modulating polynucleotides are described.

Abstract: The present invention is directed to antibodies which specifically bind to a novel .kappa./.mu.-like protein tyrosine phosphatase protein herein designated PTP .lambda. and hybridoma cell lines producing the same.

Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2D6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2D6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful in methods for screening drugs for metabolism by cytochrome P450 2D6, and in methods of screening individuals for a poor metabolizing human P450 2D6 phenotype.

Abstract: Disclosed is a monoclonal antibody which specifically reacts with active human ceruloplasmin as well as a method for diagnosing Wilson's disease using the same. The monoclonal antibody of the present invention specifically reacts with active human ceruloplasmin, it neutralizes the peroxidase activity of the active human ceruloplasmin upon binding thereto, and it does not specifically react with inactive human ceruloplasmin.

Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed. Monoclonal antibodies specific for GAD peptides and hybridoma cells producing such are also disclosed.

Abstract: The present invention provides a substantially pure phopholipase A.sub.2 protein isolated and purified from rabbit kidney cortex, having a molecular weight of 28 kDa as determined by SDS-PAGE, is calcium independent, is cytosolic, has a specific activity of approximately 1.2 .mu.mol/mg protein/minute and a pH optimum of approximately 7.5 and exhibits a preferential hydrolysis toward sn-2 fatty acid from diradylglycerophospholipids. Also provided are a first monoclonal antibody that specifically binds to the protein of claim 1 various methods of using, inhibiting or measuring said protein.

Abstract: A qualitative, quantitative, as well as local determination of pyruvatkinase (ATP:pyruvate-2-O-phosphotransferase, EC 2.7.1.40)-isoenzyme typ M2 (Tumor-M2-PK) is possible in blood, plasma, tissue culture, tissue sections as well as in the animal and human organism with the help of antibodies.Corresponding antisera are obtained if highly purified pyruvatekinase-isoenzymes type M2 (Tumor-M2-PK) or fragments of these, are used as immunogen. Preferable are antisera with monoclonal antibodies.These antibodies can be used in ELISA-Test systems for the diagnosis of cancer, to determine the malignancy of cells, to localize a tumor in an organism as well as for the therapy of cancer.

Abstract: The present invention provides such a measuring method of the CK isoform and a reagent therefor. Accordingly, the present invention provides a reagent for measuring creatine kinase (CK) activity comprising an antibody, wherein said antibody inhibits CK-M.sub.T subunit, but does not inhibit CK-M.sub.S subunit.The present invention also provides a method for measuring CK activity comprising determining an inhibition of CK of body fluids using a reagent for measuring CK activity, wherein said reagent comprises an antibody which inhibits CK-M.sub.T subunit, but does not inhibit CK-M.sub.S subunit.

Abstract: Monoclonal antibodies which bind mevalonate kinase, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting mevalonate kinase using these monoclonal antibodies.

Abstract: The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells.The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Abstract: An anti-ribonucleotide reductase (RNR) R2 subunit monoclonal antibody KM1054, KM1056 or KM1060, which belongs to the IgG2a subclass, reacts with R2 subunit of RNR, and inhibits RNR activity, is disclosed. It is effective for immunologically detecting RNR and for immunologically detecting the presence of human cancer cells.

Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

Abstract: A mammal is immunized by using an antigen of a peptide having an amino acid sequence existing in a region having low homology to amino acid sequences of tyrosinase-related proteins but included in an amino acid sequence of human tyrosinase, and then the spleen cells of the mammal is fused with cultured cells to prepare a hybridoma producing monoclonal antibody which binds to human tyrosinase and mouse tyrosinase but does not bind to the tyrosinase-related proteins.

Abstract: The present invention provides antibodies capable of discriminating between native human MGMT and an active site alkylated form of this enzyme in an immunoprecipitation procedure.Monoclonal antibodies having such discriminating ability are obtainable from hybridoma ECACC 92112510 and hybridoma ECACC 93112514, which were deposited at the European Collection of Animal Cell Cultures, UK under the Budapest Treaty on 25th Nov. 1992 and 25th Nov. 1993 respectively. The monoclonal antibody of hybridoma ECACC 92112510 has been designated Mab 5H7. The monoclonal antibody of hybridoma ECACC 93112514 has been designated Mab 3C7.

Abstract: The present invention provides monoclonal antibodies against peptides having an amino acid sequence described in Sequence No. 1 or No. 2, the peptides being found in human thymidine phosphorylase and human platelet-derived endothelial cell growth factor. The Invention also provides an immunoassay for human thymidine phosphorylase and/or human platelet-derived endothelial cell growth factor using the monoclonal antibodies. The monoclonal antibodies of the invention recognize human thymidine phosphorylase and human platelet-derived endothelial cell growth factor, and thus are useful in the diagnosis and treatment of various tumors and their metastasis and diseases accompanying abnormal angiogenesis.

Abstract: Methods and test kits are described which provide a reliable, sensitive and selective assessment of periodontal disease activity, peri-implantitis or HIV(+)-infection/AIDS-disease related periodontal diseases. The preferred methods and test kits are constructed to be easy and rapid chair-side tests. The method is based on the preparation and use of monoclonal antibodies which recognize the active mammalian matrix metalloproteinase-S (MMP-8) and is capable of differentiating between said active matrix metalloproteinase-8 and its inactive proform.

Abstract: The present invention provides a novel .beta.1.fwdarw.6 N-acetylglucosaminyltransferase, which forms core 2 oligosaccharide structures in O-glycans, and a novel acceptor molecule, leukosialin, CD43, for core 2 .beta.1.fwdarw.6 N-acetylglucosaminyltransferase activity. The amino acid sequences and nucleic acid sequences encoding these molecules, as well as active fragments thereof, also are disclosed. A method for isolating nucleic acid sequences encoding proteins having enzymatic activity is disclosed, using CHO cells that support replication of plasmid vectors having a polyoma virus origin of replication. A method to obtain a suitable cell line that expresses an acceptor molecule also is disclosed.

Abstract: The invention relates to antibodies which specifically bind to tyrosine kinase active proteins. The proteins have more than one protein kinase domain, and no SH2 domains. Exemplary proteins are the Janus Kinases, or "JAK1" and "JAK2". Both polyclonal and monoclonal antibodies are a part of the invention, as are hybridomas which produce the monoclonal antibodies.

Abstract: Agonist antibodies are disclosed which bind to the extracellular domain of receptor protein tyrosine kinases pTKs, and thereby cause dimerization and activation of the intracellular tyrosine kinase domain thereof. The antibodies are useful for activating their respective receptor and thereby enabling the role of the tyrosine kinase receptor in cell growth and/or differentiation to be studied. Chimeric proteins comprising the extracellular domain of the receptor pTKs and an immunoglobulin constant domain sequence are also disclosed.

Abstract: A process is described for obtaining highly specific pancreas elastase 1 antibodies which react both with bodily fluids and with stools. Such an antibody is obtainable by immunizing with an antigen having the amino acid sequence Thr-Met-Val-Ala-Gly-Gly-Asp-Ile-Arg (SEQ ID NO:1) or immunologically active partial peptides thereof. A test kit containing such antibodies is suitable for the diagnosis and course monitoring of chronic and acute pancreatitis as well as mucoviscidosis in bodily fluids and/or in stools.

Abstract: The invention provides method and kits for detecting a metallic cation in a sample of a body fluid. The preferred method and kits include the use of at least two different types of antibodies having different specificities. In the preferred method, the sample of body fluid can be contacted with an effective amount of a capture antibody specific for a naturally occurring polypeptide that can bind the metallic cation to form a first antigen-antibody complex. An effective amount of an antibody specific for an epitope on a metallic cation-naturally occurring polypeptide complex or an antibody specific for a metallic cation is added to the first antigen-antibody complex to form a second antigen-antibody complex. The amount of the metallic cation in the sample of body fluid is determined by detecting the amount of the second antigen-antibody complex.